96 related articles for article (PubMed ID: 11432797)
21. Treatment of chronic hepatitis C in patients who failed interferon monotherapy: effects of higher doses of interferon and ribavirin combination therapy. The Virginia Cooperative Hepatitis Treatment Group.
Shiffman ML; Hofmann CM; Gabbay J; Luketic VA; Sterling RK; Sanyal AJ; Contos MJ; Ryan MJ; Yoshida C; Rustgi V
Am J Gastroenterol; 2000 Oct; 95(10):2928-35. PubMed ID: 11051370
[TBL] [Abstract][Full Text] [Related]
22. Chronic hepatitis C. Genotypes and response to anti-viral therapy among Saudi patients.
Al-Traif I; Handoo FA; Al-Jumah A; Al-Nasser M
Saudi Med J; 2004 Dec; 25(12):1935-8. PubMed ID: 15711670
[TBL] [Abstract][Full Text] [Related]
23. Treatment effects and predictors of a 24-week course of interferon alpha-2b plus ribavirin combination therapy for patients with chronic hepatitis C.
Tomimatsu M; Aizawa Y; Chuganji Y; Ishizuka H; Fujita Y; Aizawa R; Abe H; Matsuda T; Itou Y; Nakanishi H; Ushiyama H; Higuchi T; Fujimoto T; Endou H; Iga D; Ohta K; Kuroda H
J Gastroenterol Hepatol; 2006 Jul; 21(7):1177-83. PubMed ID: 16824072
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and tolerance of a 6-month treatment course of daily interferon-alpha 2a for chronic hepatitis C with cirrhosis. The Australian Hepatitis C Study Group.
Farrell G; Cooksley WG; Dudley FJ; Watson K
J Viral Hepat; 1997 Sep; 4(5):317-23. PubMed ID: 9310930
[TBL] [Abstract][Full Text] [Related]
25. A prospective study on treatment of chronic hepatitis C with tailored and extended interferon-alpha regimens according to pretreatment virological factors.
Yu ML; Dai CY; Chen SC; Lee LP; Huang JF; Lin ZY; Hsieh MY; Wang LY; Chuang WL; Chang WY
Antiviral Res; 2004 Jul; 63(1):25-32. PubMed ID: 15196817
[TBL] [Abstract][Full Text] [Related]
26. A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C not responding to interferon alone.
Saracco G; Ciancio A; Olivero A; Smedile A; Roffi L; Croce G; Colletta C; Cariti G; Andreoni M; Biglino A; Calleri G; Maggi G; Tappero GF; Orsi PG; Terreni N; Macor A; Di Napoli A; Rinaldi E; Ciccone G; Rizzetto M
Hepatology; 2001 Jul; 34(1):133-8. PubMed ID: 11431744
[TBL] [Abstract][Full Text] [Related]
27. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.
Torriani FJ; Rodriguez-Torres M; Rockstroh JK; Lissen E; Gonzalez-García J; Lazzarin A; Carosi G; Sasadeusz J; Katlama C; Montaner J; Sette H; Passe S; De Pamphilis J; Duff F; Schrenk UM; Dieterich DT;
N Engl J Med; 2004 Jul; 351(5):438-50. PubMed ID: 15282351
[TBL] [Abstract][Full Text] [Related]
28. Initial daily interferon administration can gain more eradication of HCV-RNA in patients with chronic hepatitis C, especially with serum intermediate viral load.
Nakamura H; Ito H; Ogawa H; Takeda A; Kanazawa S; Kuroda T; Yamamoto M; Enomoto H; Kimura Y; Zenda S; Terabayashi M; Saeki K; Noguchi S; Hara H; Uemiya M; Igarashi A; Hayashi E
Hepatogastroenterology; 1999; 46(26):1131-9. PubMed ID: 10370680
[TBL] [Abstract][Full Text] [Related]
29. [Treatment of chronic hepatitis C with PEG-interferon alpha-2b and ribavirin: 24 weeks of therapy are sufficient for HCV genotype 2 and 3].
Cornberg M; Hüppe D; Wiegand J; Felten G; Wedemeyer H; Manns MP
Z Gastroenterol; 2003 Jun; 41(6):517-22. PubMed ID: 12806536
[TBL] [Abstract][Full Text] [Related]
30. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study.
Farrell GC; Bacon BR; Goldin RD
Hepatology; 1998 Apr; 27(4):1121-7. PubMed ID: 9537453
[TBL] [Abstract][Full Text] [Related]
31. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C.
von Wagner M; Huber M; Berg T; Hinrichsen H; Rasenack J; Heintges T; Bergk A; Bernsmeier C; Häussinger D; Herrmann E; Zeuzem S
Gastroenterology; 2005 Aug; 129(2):522-7. PubMed ID: 16083709
[TBL] [Abstract][Full Text] [Related]
32. The efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients.
Yenice N; Mehtap O; Gümrah M; Arican N
Turk J Gastroenterol; 2006 Jun; 17(2):94-8. PubMed ID: 16830289
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of daily induction dosing vs standard thrice weekly dosing of interferon-alpha2B for initial treatment of chronic hepatitis C.
Gonzalez HJ; Ho SB; Gross JB; Peine C; McKee D; Smith T;
Dig Dis Sci; 2002 Apr; 47(4):784-92. PubMed ID: 11991610
[TBL] [Abstract][Full Text] [Related]
34. Studies of the effectiveness of interferon alpha treatment for chronic hepatitis C in children.
Czerwionka-Szaflarska M; Chrobot A; Szaflarska-Szczepanik A
Med Sci Monit; 2000; 6(5):964-70. PubMed ID: 11208439
[TBL] [Abstract][Full Text] [Related]
35. Long-term efficacy of recombinant interferon alpha 2a in the treatment of chronic hepatitis C: a randomized prospective study comparing two dose schedules in Chinese patients.
Yao G; Ji Y; Yang M; Xu D; Gao J; Wu X; Zhang Q; Hu D
Chin Med J (Engl); 1998 Oct; 111(10):922-6. PubMed ID: 11189241
[TBL] [Abstract][Full Text] [Related]
36. A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C relapsing after interferon monotherapy.
Saracco G; Olivero A; Ciancio A; Carenzi S; Smedile A; Cariti G; Andreoni M; Orsi PG; Biglino A; Tabone M; Roffi L; Croce G; Manca A; Tappero G; Ciccone G; Rizzetto M
Hepatology; 2002 Oct; 36(4 Pt 1):959-66. PubMed ID: 12297844
[TBL] [Abstract][Full Text] [Related]
37. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.
Bronowicki JP; Ouzan D; Asselah T; Desmorat H; Zarski JP; Foucher J; Bourlière M; Renou C; Tran A; Melin P; Hézode C; Chevalier M; Bouvier-Alias M; Chevaliez S; Montestruc F; Lonjon-Domanec I; Pawlotsky JM
Gastroenterology; 2006 Oct; 131(4):1040-8. PubMed ID: 17030174
[TBL] [Abstract][Full Text] [Related]
38. Triple antiviral re-therapy for chronic hepatitis C with interferon-alpha, ribavirin and amantadine in nonresponders to interferon-alpha and ribavirin.
Zilly M; Lingenauber C; Desch S; Väth T; Klinker H; Langmann P
Eur J Med Res; 2002 Apr; 7(4):149-54. PubMed ID: 12010649
[TBL] [Abstract][Full Text] [Related]
39. Prospective study of a high-intensity interferon-alpha regimen for chronic hepatitis C virus genotype 1b infection.
Toyoda H; Kumada T; Nakano S; Takeda I; Sugiyama K; Kiriyama S; Tanikawa M; Sone Y; Hisanaga Y; Hayashi K
Hepatogastroenterology; 2002; 49(48):1619-24. PubMed ID: 12397749
[TBL] [Abstract][Full Text] [Related]
40. Hepatitis C virus RNA level changes in sera during different regimens of treatment in patients with chronic hepatitis C.
Mazur W; Gonciarz M; Mazurek U; Jurzak M; Wilczok T; Gonciarz Z
Med Sci Monit; 2003 Aug; 9 Suppl 3():39-43. PubMed ID: 15156611
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
